CDKN2A and acute lymphoblastic leukemia: demonstrated that CDKN2A/B deletions were adverse despite allogeneic stem cell transplantation in adult Philadelphia chromosome-positive (Ph+) ALL (24, 25); further studies in a larger cohort of pediatric Ph+ ALL with CDKN2A/B deletions are needed.